The one honest exception: TB-500 works partly by mass-action, so a higher local concentration in the brief window before it disperses is at least plausible
Although the ELIXA studythe only CVD outcome trial of GLP-1 RAs published to datereported a neutral cardiovascular effect of lixisenatide, the potential cardiovascular benefits of GLP-1 RAs should not be overlooked, because high-risk subjects with established CVD were recruited in this study to delineate its cardiovascular safety within a short-term period
Others including lead, mercury, cadmium, arsenic, and aluminium have no known beneficial physiological role and are toxic at any significant accumulation level
Controlling blood sugar Many GLP-1 agonist medications are approved for type 2 diabetes
Abstract: Sinha, R., Sinha, I., Calcagnotto, A., Trushin, N., Haley, J